â– LECTURE OVERVIEW: Systemic Lupus Erythematosus (SLE) is a multi-system, autoimmune disease characterized by a profound loss of self-tolerance and the production of diverse autoantibodies.
â– IMMUNOPATHOGENIC DETAILS:
1. Clearance Defects: Defective clearance of apoptotic debris exposes self-nuclear antigens to the immune system, initiating autoantibody production.
2. Core Autoantibody Profiling:
- Antinuclear Antibodies (ANA): Target nuclear antigens. Present in >95% of patients with active SLE. (High sensitivity, low specificity; standard screening test).
- Anti-dsDNA: Highly specific for SLE (>97%). Titers correlate with disease activity and the development of severe lupus nephritis.
- Anti-Smith (Sm): Highly specific for SLE (>99%). Targets small nuclear ribonucleoproteins (snRNPs); titers do not correlate with disease activity.
- Anti-Ro (SSA) and Anti-La (SSB): Associated with neonatal lupus and congenital heart block.
â– EMERGENCY MANAGEMENT:
Acute presentation requires rapid stabilization following standard clinical guidelines. Prioritize securing the airway, maintaining hemodynamic stability, and administering targeted antidotes.
â– EPIDEMIOLOGICAL PROFILE & DENSITY CORRELATIONS:
Global burden patterns reveal notable associations with lifestyle habits, regional environmental factors, and inherited traits.
[HY-BOARD-1348]
🌟 Dynamic Clinical Key:
Antiphospholipid Antibodies (e.g., anti-beta-2-glycoprotein 1, anticardiolipin) are also common in SLE. Paradoxically, they prolong the in vitro partial thromboplastin time (aPTT) by interfering with phospholipids, but in vivo they cause a hypercoagulable state with recurrent arterial and venous thromboses. Do not delay emergency interventions for low-priority diagnostic tests. Focus screening efforts on high-risk geographic regions to maximize clinical yield.